Teleflex (NYSE:TFX) Price Target Raised to $125.00

Teleflex (NYSE:TFX) had its target price raised by Royal Bank Of Canada from $115.00 to $125.00 in a research report released on Friday morning,Benzinga reports. They currently have a sector perform rating on the medical technology company’s stock.

TFX has been the topic of several other research reports. Wall Street Zen downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Truist Financial upped their price objective on shares of Teleflex from $120.00 to $135.00 and gave the company a “hold” rating in a report on Thursday, December 18th. Needham & Company LLC raised their target price on shares of Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a report on Thursday. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a research report on Monday, December 29th. Finally, Wells Fargo & Company upped their price target on shares of Teleflex from $116.00 to $130.00 and gave the company an “equal weight” rating in a report on Friday. Two investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Teleflex has an average rating of “Hold” and a consensus target price of $140.71.

Teleflex Stock Performance

Shares of TFX stock opened at $121.95 on Friday. The business has a fifty day moving average of $111.34 and a 200 day moving average of $118.68. Teleflex has a 1 year low of $100.18 and a 1 year high of $143.32. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.54 and a quick ratio of 2.01. The firm has a market capitalization of $5.39 billion, a price-to-earnings ratio of -5.93, a price-to-earnings-growth ratio of 3.74 and a beta of 0.87.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, February 26th. The medical technology company reported $1.93 earnings per share for the quarter, missing the consensus estimate of $3.73 by ($1.80). Teleflex had a negative net margin of 30.56% and a positive return on equity of 14.30%. The firm had revenue of $569.00 million for the quarter, compared to analysts’ expectations of $912.57 million. During the same quarter in the previous year, the firm posted $3.89 EPS. The firm’s revenue for the quarter was down 28.5% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, research analysts expect that Teleflex will post 13.98 earnings per share for the current year.

Teleflex Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Friday, March 6th will be issued a $0.34 dividend. The ex-dividend date of this dividend is Friday, March 6th. This represents a $1.36 dividend on an annualized basis and a yield of 1.1%. Teleflex’s payout ratio is presently -6.62%.

Institutional Investors Weigh In On Teleflex

Several hedge funds have recently modified their holdings of the company. Empowered Funds LLC increased its stake in shares of Teleflex by 15.8% in the 1st quarter. Empowered Funds LLC now owns 1,684 shares of the medical technology company’s stock valued at $233,000 after purchasing an additional 230 shares in the last quarter. Jane Street Group LLC grew its holdings in Teleflex by 42.6% in the first quarter. Jane Street Group LLC now owns 6,343 shares of the medical technology company’s stock valued at $877,000 after purchasing an additional 1,895 shares during the period. Teacher Retirement System of Texas increased its position in shares of Teleflex by 31.5% in the second quarter. Teacher Retirement System of Texas now owns 11,819 shares of the medical technology company’s stock valued at $1,399,000 after buying an additional 2,831 shares in the last quarter. Arkadios Wealth Advisors increased its position in shares of Teleflex by 61.8% in the second quarter. Arkadios Wealth Advisors now owns 5,403 shares of the medical technology company’s stock valued at $639,000 after buying an additional 2,064 shares in the last quarter. Finally, Strs Ohio raised its stake in shares of Teleflex by 4.9% during the 2nd quarter. Strs Ohio now owns 23,067 shares of the medical technology company’s stock worth $2,730,000 after buying an additional 1,067 shares during the period. 95.62% of the stock is owned by hedge funds and other institutional investors.

Teleflex News Summary

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Wells Fargo raised its price target to $130 (from $116) and maintained an “equal weight” rating — a near-term bullish signal that can support buying interest. Read More.
• Positive Sentiment: Royal Bank of Canada raised its price target to $125 (from $115) with a “sector perform” rating — another analyst lift that helps underpin the rally. Read More.
• Positive Sentiment: Teleflex’s board declared a quarterly cash dividend of $0.34 per share (record date March 6, payable March 31), which can attract income-seeking investors and provide support. Read More.
• Positive Sentiment: The company launched a multi‑year restructuring tied to planned divestitures — investors appear to view this as steps to simplify the portfolio, cut costs and potentially unlock value. Read More.
• Neutral Sentiment: Teleflex published its Q4 presentation and full-year results (material and earnings‑call transcripts are available) — useful for modeling but not a driver by itself. Read More.
• Negative Sentiment: Q4 results missed materially: EPS $1.93 vs. consensus ~$3.73 and revenue $569M vs. ~$912.6M — revenue fell ~28.5% year-over-year and margins contracted, a clear near-term negative for earnings momentum. Read More.
• Negative Sentiment: FY‑2026 guidance was significantly reduced: EPS guidance of $6.25–$6.55 and revenue guidance around $2.3B vs. street expectations materially higher (~$15 EPS and ~$3.7B revenue), which is a major downward re‑rating of near-term expectations. Read More.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.